Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Inbrija is a prescription levodopa inhalation powder for intermittent treatment of OFF episodes in patients with Parkinson disease who take carbidopa and levodopa. Each capsule contains 42 mg of levodopa and is used only with the Inbrija inhaler.
read more about inbrija ...Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain. Increasing dopamine activity helps relieve Parkinson symptoms during an OFF episode. Inbrija is used together with a regular carbidopa and levodopa regimen rather than as a replacement for it.
Inbrija is used in patients with Parkinson disease who are treated with carbidopa and levodopa and have intermittent OFF episodes. It is not recommended in patients with asthma, chronic obstructive pulmonary disease, or another chronic underlying lung disorder due to bronchospasm risk.
One dose consists of inhaling the contents of two 42 mg capsules for a total of 84 mg when OFF symptoms return. A patient can use up to five doses per day. The maximum dose for one OFF period is 84 mg and the maximum daily dose is 420 mg. The capsules are inhaled and are not swallowed.
Serious concerns include falling asleep during daily activities, withdrawal-related fever and confusion, hallucinations or psychotic behavior, compulsive behaviors, dyskinesia, bronchospasm, and worsening glaucoma. Use with a nonselective monoamine oxidase inhibitor or within two weeks of stopping one is contraindicated.
Inbrija treats intermittent OFF episodes in patients with Parkinson disease who take carbidopa and levodopa.
One dose is the inhaled contents of two 42 mg capsules for a total of 84 mg.
The maximum is five doses or 420 mg in one day.
No. The capsules are used only with the Inbrija inhaler and are not swallowed.
A 12-Month Dose-Level Blinded Safety and Efficacy Study of Levodopa Inhalation Powder in Patients With Parkinson's Disease. https://pubmed.ncbi.nlm.nih.gov/33130477/. Date Accessed October 2, 2026.
DailyMed - INBRIJA - levodopa inhalation powder. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a906f8e1-6e1c-480a-8276-c01bc65dd3be. Date Accessed October 2, 2026.
INBRIJA Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209184s013.pdf. Date Accessed October 2, 2026.
Levodopa Oral Inhalation - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a619018.html. Date Accessed October 2, 2026.
Safety and Efficacy of CVT-301 Levodopa Inhalation Powder on Motor Function During OFF Periods in Patients With Parkinson's Disease. https://pubmed.ncbi.nlm.nih.gov/30663606/. Date Accessed October 2, 2026.